Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This study is looking at a new drug called selumetinib to see if it works as well as (or better than) the usual treatment (drugs called carboplatin/vincristine) for children with a type of brain tumor called low grade glioma. This study is also checking if selumetinib is better for helping improve vision for children with these tumors. Selumetinib works by blocking a substance called an enzyme that the tumor cells need to grow, which can help kill them. The regular treatment uses different drugs that stop tumor cells from growing in different ways. This study will compare to see which method is better. 

Inclusion Criteria

• Patients must be >= 2 years and =< 21 years at the time of enrollment
• Patients must have neurofibromatosis type 1 (NF1), newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery
• Additional inclusion criteria applies for patients with optic pathway gliomas, if applicable
• Patient must meet all of the bloodwork and organ function requirements outlined in the study
• Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment
• Patients must have an adequate performance status 
• Patients must have the ability to swallow whole capsules
• All patients and/or their parents or legal guardians must sign a written informed consent.

Other inclusion and exclusion criteria applies and will be discussed with you by the study team.

Go to Health Care Provider version

Centres

Study Description

(As seen on the Australian & New Zealand Childrens Haematology/Oncology Group website - https://anzchog.org/clinic-trails/connect-1903-a-pilot-and-surgical-study-of-larotrectinib-for-treatment-of-children-with-newly-diagnosed-high-grade-glioma-with-ntrk-fusion/ )

Recent research shows that a new oral tablet drug, larotrectinib, has produced promising results by shrinking some solid tumours that have an abnormal or mutated NTRK gene in adults and children.

High grade gliomas (HGG) are fast growing, aggressive brain cancers and if they recur after initial treatment, there are no effective treatment options. This study will investigate if larotrectinib alone as well as Larotrectinib  in combination with chemotherapy or radiotherapy can  be of benefit in children with high grade gliomas with the mutated NTRK gene. This international trial will study how well the drug is tolerated and its effectiveness to shrink these tumours when used alone or when given with standard chemotherapy or after radiation.

Inclusion Criteria

(As seen on the Australian & New Zealand Childrens Haematology/Oncology Group website - https://anzchog.org/clinic-trails/connect-1903-a-pilot-and-surgical-study-of-larotrectinib-for-treatment-of-children-with-newly-diagnosed-high-grade-glioma-with-ntrk-fusion/ )

• Patient must be 21 years old or younger and newly diagnosed with high grade glioma (HGG)
• The tumour must have a genetic anomaly called an NTRK fusion for the patient to qualify
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

The purpose of this study is to find out what effects new combinations of treatment will help in treating a cancer called lymphoma. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Inclusion Criteria

• Participants must be between 16 to 65 years old to participate
• Participants must have one of the following diagnoses: 
  • Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma)
  • Previous indolent lymphoma with transformation to diffuse large B-cell lymphoma at most recent relapse
  • Unclassifiable B-cell lymphoma with indeterminate features between diffuse large B-cell lymphoma and Burkitt lymphoma
• Participants must have the presence of a protein called CD20
• Must meet all bloodwork requirements
• Participants who can bare children must have a negative pregnancy test prior to starting 
• Participants must be willing to sign a consent form and agree to the study schedule

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express two chimeric antigen receptors (CARs). One is to recognize CD19 and the other is to recognize CD22, both of which are proteins expressed on the surface of the leukemic cell in patients with CD19+CD22+ leukemia. The CAR enables the T-cell to recognize and kill the leukemic cell through recognition of CD19 and CD22. This is a phase 1 study designed to determine the safety of the CAR+ T-cells and the feasibility of making enough to treat patients with CD19+CD22+ leukemia.

Inclusion Criteria

• First 2 subjects: male and female subjects age ≥18 and < 27 years (as of 2/16/18 the first 2 subjects were enrolled and treated); subsequent subjects: male and female subjects age ≥12 months of age and <27 years.
• Diagnosis of CD19+22+ leukemia relapsed or refractory
• Asymptomatic from CNS involvement
• Free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollment
• Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy
• No prior genetically modified cell therapy that is still detectable or virotherapy
• Willing to participate in long-term follow-up for up to 15 years, if enrolled in the study and receive T cell infusion

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This study evaluates how effective a drug called plixorafenib is in participants with solid tumors or central nervous system (CNS) tumors with a genetic mutation called a BRAF fusion/BRAF V600E mutation that have progressed or come back.

Inclusion Criteria

• Male and female, ≥10 years of age, and weighing ≥30 kg.
• Diagnosis of a solid tumor or primary CNS tumor that has previously been treated with other standard therapies
• Documentation of BRAF gene fusion in tumor
• Willingness to provide informed consent and comply with study requirements 

Other inclusion and exclusion criteria apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This is a study of a new oral medication called gilteritinib, to be given in combination with chemotherapy to patients that have acute myeloid leukemia that has come back (relapse). The leukemia cells need to have a genetic change called "FLT3 ITD" for the patient to be considered for the study. Gilteritinib is an anti-cancer medication that blocks the FLT3 protein when it is abnormal in a leukemia cell.

The main goal of the study will be to establish an optimally safe and biologically active dose of the medication, and then to determine the effect it has on leukemia disease in combination with chemotherapy.

Inclusion Criteria

• Age from 6 months to 21 years
• Acute myeloid leukemia that has come back (relapse) and has a genetic change called "FLT3 ITD"
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is a phase 3 study for patients with newly diagnosed diffuse glioma. To be eligible for this study, the participant's cancer must have a mutation called H3 K27M. This study explores whether adding treatment with the experimental drug called ONC201 after radiotherapy is effective in patients with this type of cancer. 

Inclusion Criteria

• Able to understand the study procedures and agree to participate in the study by providing written informed consent and assent when applicable.
• Body weight ≥ 10 kg
• A new diagnosis of diffuse glioma with a H3 K27M mutation 
• Received frontline radiotherapy (radiation) within 2-6 weeks of starting this study
• Patient must be capable of self-care but may be unable to engage in normal activities or perform active work

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

Go to Health Care Provider version

Centres

Study Description

In this study, researchers are trying to learn more about the safety of the combination of study medicines Avelumab and Lenvatinib, and how well they work for children and young people with central nervous system tumours where previous treatment have not worked.

If you/your child participate in this study, you/they will be asked to join one of the two parts.

Part 1 will help us learn the best dose of the drug to take, and in Part 2, we will use the information obtained in Part 1 to continue to give the study drug and monitor how it is working.

Inclusion Criteria

• Patients must have a confirmed diagnosis of a high-grade brain tumour
• Patients must be between the ages of 2-18 years old
• Patients must have a cancer that has come back (relapsed) after a previous treatment
• Patients must be able to walk and do routine activities for more than half of their normal waking hours
• Patients must have a willingness to complete clinical assessments throughout the study (electronic, paper and/or interviewer methods)

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.